Novel Agents in Development for Peripheral T-Cell Lymphoma

Seminars in Hematology

Volumn 47, Issue SUPPL. 1, 2010, Pages

  O'Connor, Owen A ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; BELINOSTAT; BENZAMIDE DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DOXORUBICIN; FORODESINE; GEMCITABINE; LENALIDOMIDE; METHOTREXATE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NELARABINE; PANOBINOSTAT; PENTOSTATIN; PRALATREXATE; PREDNISONE; PROTEASOME INHIBITOR; ROMIDEPSIN; VINCRISTINE; VORINOSTAT;

ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; LOW DRUG DOSE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL;

AMINOPTERIN; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, T-CELL, PERIPHERAL; PURINE NUCLEOSIDES; PYRAZINES; PYRIMIDINONES; SALVAGE THERAPY; THALIDOMIDE;

EID: 77950616726     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.014     Document Type: Article

References (24)

1. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
2. ODAC briefing document-Pralatrexate injection. US Food and Drug Administration, 2009 Allos Therapeutics I, Accessed January 11, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180636.pdf.
3. Olsen E.A., Kim Y.H., Kuzel T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
4. Piekarz R., Wright J., Frye R., et al. Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) [abstr 1567]. Blood 2008, 112:555.
5. Toner L.E., Vrhovac R., Smith E.A., et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:924-932.
6. Zinzani P.L., Magagnoli M., Bendandi M., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351-1353.
7. Sallah S., Wan J.Y., Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185-187.
8. Horwitz S.M., Vose J.M., Advani R., et al. Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase I results [abstr 1674]. Blood 2009, 114:667.
9. Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:4293-4297.
10. Lee J., Suh C., Kang H.J., et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008, 19:2079-2083.
11. Paoluzzi L., Scotto L., Seshan V.E., O'Connor O.A. Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) [abstr 8584]. J Clin Oncol 2009, 27:454s.
12. Wilson W., O'Connor O., Roberts A.W., et al. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [abstr 8574]. J Clin Oncol 2009, 27:452s.
13. Wilson W.H., O'Connor O., Czuczman M.S., et al. Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies [abstr 2108]. Blood 2008, 112:734.
14. Paoluzzi L., Gonen M., Bhagat G., et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008, 112:2906-2916.
15. Dueck G.S., Chua N., Prasad A., et al. Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases [abstr 8524]. J Clin Oncol 2009, 27:439s.
16. Sakiyama T. [Purine nucleoside phosphorylase (PNP) deficiency]. Nippon Rinsho 1996, 54:3328-3332.
17. Furman R.R., Gore L., Ravandi F., Hoelzer D. Forodesine IV (Bcx-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a phase II study (interim report) [abstr 1851]. Blood 2006, 108:524a.
18. Dearden C., Matutes E., Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 1991, 64:903-906.
19. Sallah S., Wan J.Y., Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185-187.
20. Enblad G., Hagberg H., Erlanson M. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
21. Tsimberidou A.M., Giles F., Duvic M., Fayad L., Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004, 100:342-349.
22. Dang N.H., Pro B., Hagemeister F.B. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
23. Reiman T., Finch D., Chua N., et al. First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma. Blood 2007, 110. Abstract 2579.
24. Czuczman M.S., Porcu P., Johnson J., et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma 2007, 48:97-103.